FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124578085> ?p ?o ?g. }

• W3124578085 endingPage "239" @default.
• W3124578085 startingPage "239" @default.
• W3124578085 abstract "239 Background: After trastuzumab (T) approval for advanced HER2-positive E/GEJ-AC, HER2 testing has increased in patients (pts) with resectable disease. Neoadjuvant carboplatin/paclitaxel chemoradiation (nCP-CRT) is a common therapy approach. We performed the largest evaluation, to our knowledge, of the prognostic impact of HER2 in E/GEJ-AC pts treated with nCP-CRT. Methods: We retrospectively reviewed medical records of all trimodality-eligible (T 2 + or N + ) pts with E/GEJ-AC who started nCP-CRT (usually 50.4 Gy) with planned surgery at Mayo Clinic (2014-2019). HER2 was tested using standard criteria for HER2 positivity (ie, immunohistochemistry 3+ or amplification by in situ hybridization). Clinicopathologic data and time to recurrence (TTR), disease free survival (DFS), overall survival (OS), survival after recurrence (SAR), and pathologic complete response (pCR – ie, no residual tumor in primary or nodes) were collected. Kaplan Meier and multivariate Cox analysis were used. Results: Of 161 consecutive eligible pts, HER2 status was available in 107 pts (HER2-positive n=26, HER2-negative n=81) of whom n=82 had surgery and n=19 had pCR. Most tumors were clinical T3 (80%) or N+ (81%), histologic grade 3 of 3 (62%). HER2 positivity was significantly associated with lower grade, but not with age, clinical T or N, or ECOG performance status (PS). A similar proportion of HER2-positive ( vs negative) pts had surgery. Among pts who had surgery, pCR rates were lower in HER2-positive ( vs negative) pts (11% [2/19] vs 27% [17/63]). After a median follow up of 23 mo, DFS and TTR were significantly shorter in HER2 positive ( vs negative) pts, independent of other pretreatment covariables (Table). Yet OS was comparable. Lung recurrence was enriched in HER2 positive ( vs negative) pts. Among pts with recurrence, SAR was longer in HER2-positive vs -negative pts. A total of 53% (10/19) of previously HER2-positive pts received T-based therapy after recurrence, and these pts were the drivers of favorable SAR (median 22 mo in n=10 HER2-positive pts who received T vs 11 mo in n=9 HER2-positive pts who did not receive T vs 11 mo in n=40 HER2-negative pts; P log-rank=.01). Conclusions: HER2 positivity ( vs negativity) is independently associated with shorter TTR and DFS, but more comparable OS. The adverse association of HER2 on tumor response and TTR may have been largely overcome through enhanced survival after recurrence, although OS data are maturing. These data may have implications for the design of endpoints in future curative-intent anti-HER2 trials. [Table: see text]" @default.
• W3124578085 created "2021-02-01" @default.
• W3124578085 creator A5006194799 @default.
• W3124578085 creator A5010602161 @default.
• W3124578085 creator A5016778479 @default.
• W3124578085 creator A5017792432 @default.
• W3124578085 creator A5018405630 @default.
• W3124578085 creator A5019214686 @default.
• W3124578085 creator A5026832611 @default.
• W3124578085 creator A5042636908 @default.
• W3124578085 creator A5043434997 @default.
• W3124578085 creator A5045186065 @default.
• W3124578085 creator A5050766065 @default.
• W3124578085 creator A5059012052 @default.
• W3124578085 creator A5066263748 @default.
• W3124578085 creator A5066586257 @default.
• W3124578085 creator A5070955874 @default.
• W3124578085 creator A5071942279 @default.
• W3124578085 creator A5074277192 @default.
• W3124578085 creator A5078619764 @default.
• W3124578085 creator A5088854603 @default.
• W3124578085 creator A5090608376 @default.
• W3124578085 date "2021-01-20" @default.
• W3124578085 modified "2023-09-23" @default.
• W3124578085 title "HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation." @default.
• W3124578085 doi "https://doi.org/10.1200/jco.2021.39.3_suppl.239" @default.
• W3124578085 hasPublicationYear "2021" @default.
• W3124578085 type Work @default.
• W3124578085 sameAs 3124578085 @default.
• W3124578085 citedByCount "0" @default.
• W3124578085 crossrefType "journal-article" @default.
• W3124578085 hasAuthorship W3124578085A5006194799 @default.
• W3124578085 hasAuthorship W3124578085A5010602161 @default.
• W3124578085 hasAuthorship W3124578085A5016778479 @default.
• W3124578085 hasAuthorship W3124578085A5017792432 @default.
• W3124578085 hasAuthorship W3124578085A5018405630 @default.
• W3124578085 hasAuthorship W3124578085A5019214686 @default.
• W3124578085 hasAuthorship W3124578085A5026832611 @default.
• W3124578085 hasAuthorship W3124578085A5042636908 @default.
• W3124578085 hasAuthorship W3124578085A5043434997 @default.
• W3124578085 hasAuthorship W3124578085A5045186065 @default.
• W3124578085 hasAuthorship W3124578085A5050766065 @default.
• W3124578085 hasAuthorship W3124578085A5059012052 @default.
• W3124578085 hasAuthorship W3124578085A5066263748 @default.
• W3124578085 hasAuthorship W3124578085A5066586257 @default.
• W3124578085 hasAuthorship W3124578085A5070955874 @default.
• W3124578085 hasAuthorship W3124578085A5071942279 @default.
• W3124578085 hasAuthorship W3124578085A5074277192 @default.
• W3124578085 hasAuthorship W3124578085A5078619764 @default.
• W3124578085 hasAuthorship W3124578085A5088854603 @default.
• W3124578085 hasAuthorship W3124578085A5090608376 @default.
• W3124578085 hasConcept C121608353 @default.
• W3124578085 hasConcept C126322002 @default.
• W3124578085 hasConcept C141071460 @default.
• W3124578085 hasConcept C143998085 @default.
• W3124578085 hasConcept C2776694085 @default.
• W3124578085 hasConcept C2778239845 @default.
• W3124578085 hasConcept C2778292576 @default.
• W3124578085 hasConcept C2779786085 @default.
• W3124578085 hasConcept C2781182431 @default.
• W3124578085 hasConcept C2781451048 @default.
• W3124578085 hasConcept C2909600360 @default.
• W3124578085 hasConcept C50382708 @default.
• W3124578085 hasConcept C530470458 @default.
• W3124578085 hasConcept C71924100 @default.
• W3124578085 hasConcept C90924648 @default.
• W3124578085 hasConceptScore W3124578085C121608353 @default.
• W3124578085 hasConceptScore W3124578085C126322002 @default.
• W3124578085 hasConceptScore W3124578085C141071460 @default.
• W3124578085 hasConceptScore W3124578085C143998085 @default.
• W3124578085 hasConceptScore W3124578085C2776694085 @default.
• W3124578085 hasConceptScore W3124578085C2778239845 @default.
• W3124578085 hasConceptScore W3124578085C2778292576 @default.
• W3124578085 hasConceptScore W3124578085C2779786085 @default.
• W3124578085 hasConceptScore W3124578085C2781182431 @default.
• W3124578085 hasConceptScore W3124578085C2781451048 @default.
• W3124578085 hasConceptScore W3124578085C2909600360 @default.
• W3124578085 hasConceptScore W3124578085C50382708 @default.
• W3124578085 hasConceptScore W3124578085C530470458 @default.
• W3124578085 hasConceptScore W3124578085C71924100 @default.
• W3124578085 hasConceptScore W3124578085C90924648 @default.
• W3124578085 hasIssue "3_suppl" @default.
• W3124578085 hasLocation W31245780851 @default.
• W3124578085 hasOpenAccess W3124578085 @default.
• W3124578085 hasPrimaryLocation W31245780851 @default.
• W3124578085 hasRelatedWork W1984009717 @default.
• W3124578085 hasRelatedWork W2004818507 @default.
• W3124578085 hasRelatedWork W2013223170 @default.
• W3124578085 hasRelatedWork W2066747782 @default.
• W3124578085 hasRelatedWork W2367105124 @default.
• W3124578085 hasRelatedWork W2937445726 @default.
• W3124578085 hasRelatedWork W2969515167 @default.
• W3124578085 hasRelatedWork W4252376471 @default.
• W3124578085 hasRelatedWork W812572266 @default.
• W3124578085 hasRelatedWork W2342209702 @default.
• W3124578085 hasVolume "39" @default.
• W3124578085 isParatext "false" @default.
• W3124578085 isRetracted "false" @default.

• next